Skip to main content
SpringerLink
Log in

Management of Stable Ischemic Heart Disease in Women

  • Chapter
  • First Online:
Management of Cardiovascular Disease in Women

  • 905 Accesses

Abstract

Cardiovascular disease (CVD) remains the most common cause of death in women living in developed countries and outnumbers death from all forms of cancer combined [1]. Since 1984, the number of CVD deaths for females has exceeded those for males. With the advances in the diagnosis and treatment of coronary artery disease (CAD), there have been significant decreases in cardiovascular mortality seen in both sexes, with the major decline for women occurring after the year 2000 [2]. However, this reduction in mortality among women has remained less pronounced as compared with men [3]. The reason for this disparity may be gender differences in the pathophysiology of CAD or lower awareness of coronary disease in women leading to decreased implementation of evidence based care [4]. The Yentl syndrome (as described in 1991) pointed out the ubiquitous misrecognition of CVD as an affliction of men, with women seeming to require a higher burden of proof in order to receive appropriate diagnostic tests and therapeutic interventions [5]. There are recognized gender differences including a notable 10 year delay in the onset of ischemic heart disease (IHD) in women compared to men, that have been attributed to the protective effect of estrogen [6].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wenger NK. Women and coronary heart disease: a century after Herrick: understudied, underdiagnosed, and undertreated. Circulation. 2012;126(5):604–11.

    Article  PubMed  Google Scholar 

  2. Roger VL, et al. Heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2–220.

    Article  PubMed  Google Scholar 

  3. Bellasi A, et al. New insights into ischemic heart disease in women. Cleve Clin J Med. 2007;74(8):585–94.

    Article  PubMed  Google Scholar 

  4. Gupta A, et al. Most important outcomes research papers on cardiovascular disease in women. Circ Cardiovasc Qual Outcomes. 2013;6(1):e1–7.

    Article  PubMed  Google Scholar 

  5. Healy B. The Yentl syndrome. N Engl J Med. 1991;325(4):274–6.

    Article  PubMed  CAS  Google Scholar 

  6. Bairey Merz CN, et al. Proceedings from the scientific symposium: sex differences in cardiovascular disease and implications for therapies. J Womens Health (Larchmt). 2010;19(6):1059–72.

    Article  Google Scholar 

  7. Daly C, et al. Gender differences in the management and clinical outcome of stable angina. Circulation. 2006;113(4):490–8.

    Article  PubMed  Google Scholar 

  8. Mosca L, et al. AHA/ACC scientific statement: consensus panel statement. Guide to preventive cardiology for women. American Heart Association/American College of Cardiology. J Am Coll Cardiol. 1999;33(6):1751–5.

    Article  PubMed  CAS  Google Scholar 

  9. Go AS, et al. Executive summary: heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation. 2013;127(1):143–52.

    Article  PubMed  Google Scholar 

  10. Zuchi C, Tritto I, Ambrosio G. Angina pectoris in women: focus on microvascular disease. Int J Cardiol. 2013;163(2):132–40.

    Article  PubMed  Google Scholar 

  11. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J. 1986;111(2):383–90.

    Article  PubMed  CAS  Google Scholar 

  12. Fihn SD, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60(24):e44–164.

    Article  PubMed  Google Scholar 

  13. NHS-National Institute for Health and Clinical Excellence. Management of stable angina National Clinical Guideline Centre. 2011. http://www.nice.org.uk/guidance/CG126.

  14. Milner KA, et al. Gender differences in symptom presentation associated with coronary heart disease. Am J Cardiol. 1999;84(4):396–9.

    Article  PubMed  CAS  Google Scholar 

  15. Pepine CJ. Angina pectoris in a contemporary population: characteristics and therapeutic implications. TIDES Investigators. Cardiovasc Drugs Ther. 1998;12 Suppl 3:211–6.

    Article  PubMed  Google Scholar 

  16. Hemingway H, et al. Prevalence of angina in women versus men: a systematic review and meta-analysis of international variations across 31 countries. Circulation. 2008;117(12):1526–36.

    Article  PubMed  Google Scholar 

  17. Steg PG, et al. Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. Eur Heart J. 2012;33(22):2831–40.

    Article  PubMed Central  PubMed  Google Scholar 

  18. Bugiardini R, et al. Factors influencing underutilization of evidence-based therapies in women. Eur Heart J. 2011;32(11):1337–44.

    Article  PubMed  CAS  Google Scholar 

  19. Daly CA, et al. The clinical characteristics and investigations planned in patients with stable angina presenting to cardiologists in Europe: from the Euro Heart Survey of Stable Angina. Eur Heart J. 2005;26(10):996–1010.

    Article  PubMed  Google Scholar 

  20. Dawber TR, Kannel WB. The Framingham study. An epidemiological approach to coronary heart disease. Circulation. 1966;34(4):553–5.

    Article  PubMed  CAS  Google Scholar 

  21. D’Agostino Sr RB, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743–53.

    Article  PubMed  Google Scholar 

  22. Ridker PM, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297(6):611–9.

    Article  PubMed  CAS  Google Scholar 

  23. Vaccarino V, et al. Ischaemic heart disease in women: are there sex differences in pathophysiology and risk factors? Position paper from the working group on coronary pathophysiology and microcirculation of the European Society of Cardiology. Cardiovasc Res. 2011;90(1):9–17.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  24. Vaccarino V, et al. Sex differences in mortality after acute myocardial infarction: changes from 1994 to 2006. Arch Intern Med. 2009;169(19):1767–74.

    Article  PubMed Central  PubMed  Google Scholar 

  25. Shaw LJ, et al. Impact of ethnicity and gender differences on angiographic coronary artery disease prevalence and in-hospital mortality in the American College of Cardiology-National Cardiovascular Data Registry. Circulation. 2008;117(14):1787–801.

    Article  PubMed  Google Scholar 

  26. Shaw LJ, et al. Insights from the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation (WISE) Study: part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol. 2006;47(3 Suppl):S4–20.

    Article  PubMed  Google Scholar 

  27. Shaw LJ, et al. The economic burden of angina in women with suspected ischemic heart disease: results from the National Institutes of Health–National Heart, Lung, and Blood Institute–sponsored Women’s Ischemia Syndrome Evaluation. Circulation. 2006;114(9):894–904.

    Article  PubMed  Google Scholar 

  28. Johnson BD, et al. Persistent chest pain predicts cardiovascular events in women without obstructive coronary artery disease: results from the NIH-NHLBI-sponsored Women’s Ischaemia Syndrome Evaluation (WISE) study. Eur Heart J. 2006;27(12):1408–15.

    Article  PubMed  Google Scholar 

  29. Sharaf BL, et al. Detailed angiographic analysis of women with suspected ischemic chest pain (pilot phase data from the NHLBI-sponsored Women’s Ischemia Syndrome Evaluation [WISE] Study Angiographic Core Laboratory). Am J Cardiol. 2001;87(8):937–41; A3.

    Article  PubMed  CAS  Google Scholar 

  30. Bairey Merz CN, et al. Insights from the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation (WISE) Study: part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol. 2006;47(3 Suppl):S21–9.

    Article  PubMed  Google Scholar 

  31. Sheifer SE, et al. Sex differences in coronary artery size assessed by intravascular ultrasound. Am Heart J. 2000;139(4):649–53.

    Article  PubMed  CAS  Google Scholar 

  32. Mintz GS, et al. Contribution of inadequate arterial remodeling to the development of focal coronary artery stenoses. An intravascular ultrasound study. Circulation. 1997;95(7):1791–8.

    Article  PubMed  CAS  Google Scholar 

  33. Schoenhagen P, et al. Arterial remodeling and coronary artery disease: the concept of “dilated” versus “obstructive” coronary atherosclerosis. J Am Coll Cardiol. 2001;38(2):297–306.

    Article  PubMed  CAS  Google Scholar 

  34. Khuddus MA, et al. An intravascular ultrasound analysis in women experiencing chest pain in the absence of obstructive coronary artery disease: a substudy from the National Heart, Lung and Blood Institute-Sponsored Women’s Ischemia Syndrome Evaluation (WISE). J Interv Cardiol. 2010;23(6):511–9.

    Article  PubMed Central  PubMed  Google Scholar 

  35. Reynolds HR, et al. Mechanisms of myocardial infarction in women without angiographically obstructive coronary artery disease. Circulation. 2011;124(13):1414–25.

    Article  PubMed Central  PubMed  Google Scholar 

  36. Collins P. Coronary flow reserve. Br Heart J. 1993;69(4):279–81.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  37. Maseri A, et al. Mechanisms of angina pectoris in syndrome X. J Am Coll Cardiol. 1991;17(2):499–506.

    Article  PubMed  CAS  Google Scholar 

  38. Cannon 3rd RO, Epstein SE. “Microvascular angina” as a cause of chest pain with angiographically normal coronary arteries. Am J Cardiol. 1988;61(15):1338–43.

    Article  PubMed  Google Scholar 

  39. Reis SE, et al. Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the NHLBI WISE study. Am Heart J. 2001;141(5):735–41.

    Article  PubMed  CAS  Google Scholar 

  40. Reis SE, et al. Coronary flow velocity response to adenosine characterizes coronary microvascular function in women with chest pain and no obstructive coronary disease. Results from the pilot phase of the Women’s Ischemia Syndrome Evaluation (WISE) study. J Am Coll Cardiol. 1999;33(6):1469–75.

    Article  PubMed  CAS  Google Scholar 

  41. Wei J, et al. Safety of coronary reactivity testing in women with no obstructive coronary artery disease: results from the NHLBI-sponsored WISE (Women’s Ischemia Syndrome Evaluation) study. JACC Cardiovasc Interv. 2012;5(6):646–53.

    Article  PubMed Central  PubMed  Google Scholar 

  42. Kemp Jr HG, et al. The anginal syndrome associated with normal coronary arteriograms. Report of a six year experience. Am J Med. 1973;54(6):735–42.

    Article  PubMed  Google Scholar 

  43. Kothawade K, Bairey Merz CN. Microvascular coronary dysfunction in women: pathophysiology, diagnosis, and management. Curr Probl Cardiol. 2011;36(8):291–318.

    PubMed Central  PubMed  Google Scholar 

  44. Arthur HM, et al. Women, cardiac syndrome X, and microvascular heart disease. Can J Cardiol. 2012;28(2 Suppl):S42–9.

    Article  PubMed  Google Scholar 

  45. Kaski JC, et al. Transient myocardial ischemia during daily life in patients with syndrome X. Am J Cardiol. 1986;58(13):1242–7.

    Article  PubMed  CAS  Google Scholar 

  46. Nugent L, Mehta PK, Bairey Merz CN. Gender and microvascular angina. J Thromb Thrombolysis. 2011;31(1):37–46.

    Article  PubMed Central  PubMed  Google Scholar 

  47. Marroquin OC, et al. Inflammation, endothelial cell activation, and coronary microvascular dysfunction in women with chest pain and no obstructive coronary artery disease. Am Heart J. 2005;150(1):109–15.

    Article  PubMed  Google Scholar 

  48. Kannel WB, Feinleib M. Natural history of angina pectoris in the Framingham study. Prognosis and survival. Am J Cardiol. 1972;29(2):154–63.

    Article  PubMed  CAS  Google Scholar 

  49. Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386):782–8.

    Article  PubMed  CAS  Google Scholar 

  50. Kaski JC, et al. Cardiac syndrome X: clinical characteristics and left ventricular function. Long-term follow-up study. J Am Coll Cardiol. 1995;25(4):807–14.

    Article  PubMed  CAS  Google Scholar 

  51. Humphries KH, et al. Angina with “normal” coronary arteries: sex differences in outcomes. Am Heart J. 2008;155(2):375–81.

    Article  PubMed  Google Scholar 

  52. Delcour KS, et al. Outcomes in patients with abnormal myocardial perfusion imaging and normal coronary angiogram. Angiology. 2009;60(3):318–21.

    Article  PubMed  Google Scholar 

  53. Gulati M, et al. Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women’s Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. Arch Intern Med. 2009;169(9):843–50.

    Article  PubMed Central  PubMed  Google Scholar 

  54. Pepine CJ, et al. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women’s Ischemia Syndrome Evaluation) study. J Am Coll Cardiol. 2010;55(25):2825–32.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  55. Boden WE, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503–16.

    Article  PubMed  CAS  Google Scholar 

  56. Spertus JA, et al. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol. 1995;25(2):333–41.

    Article  PubMed  CAS  Google Scholar 

  57. Hlatky MA, et al. A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index). Am J Cardiol. 1989;64(10):651–4.

    Article  PubMed  CAS  Google Scholar 

  58. Maddox TM, et al. Utilization of secondary prevention therapies in patients with nonobstructive coronary artery disease identified during cardiac catheterization: insights from the National Cardiovascular Data Registry Cath-PCI Registry. Circ Cardiovasc Qual Outcomes. 2010;3(6):632–41.

    Article  PubMed  Google Scholar 

  59. Ogden CL, et al. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA. 2006;295(13):1549–55.

    Article  PubMed  CAS  Google Scholar 

  60. Poirier P, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006;113(6):898–918.

    Article  PubMed  Google Scholar 

  61. Gulati M, Shaw LJ, Bairey Merz CN. Myocardial ischemia in women: lessons from the NHLBI WISE study. Clin Cardiol. 2012;35(3):141–8.

    Article  PubMed Central  PubMed  Google Scholar 

  62. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332(7533):73–8.

    Article  PubMed Central  PubMed  Google Scholar 

  63. Wenger NK. Coronary heart disease: the female heart is vulnerable. Prog Cardiovasc Dis. 2003;46(3):199–229.

    Article  PubMed  Google Scholar 

  64. Gami AS, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007;49(4):403–14.

    Article  PubMed  CAS  Google Scholar 

  65. Bellamy L, et al. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335(7627):974.

    Article  PubMed Central  PubMed  Google Scholar 

  66. Satcher D, Thompson TG, Koplan JP. Women and smoking: a report of the Surgeon General. Nicotine Tob Res. 2002;4(1):7–20.

    Article  PubMed  Google Scholar 

  67. Barua RS, et al. Heavy and light cigarette smokers have similar dysfunction of endothelial vasoregulatory activity: an in vivo and in vitro correlation. J Am Coll Cardiol. 2002;39(11):1758–63.

    Article  PubMed  CAS  Google Scholar 

  68. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA. 2003;290(1):86–97.

    Article  PubMed  Google Scholar 

  69. Yusuf S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet. 2004;364(9438):937–52.

    Article  PubMed  Google Scholar 

  70. Milani RV, Lavie CJ, Mehra MR. Reduction in C-reactive protein through cardiac rehabilitation and exercise training. J Am Coll Cardiol. 2004;43(6):1056–61.

    Article  PubMed  CAS  Google Scholar 

  71. Hambrecht R, et al. Regular physical activity improves endothelial function in patients with coronary artery disease by increasing phosphorylation of endothelial nitric oxide synthase. Circulation. 2003;107(25):3152–8.

    Article  PubMed  CAS  Google Scholar 

  72. Goldsmith RL, Bloomfield DM, Rosenwinkel ET. Exercise and autonomic function. Coron Artery Dis. 2000;11(2):129–35.

    Article  PubMed  CAS  Google Scholar 

  73. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86.

    Article  Google Scholar 

  74. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038):1329–39.

    Article  Google Scholar 

  75. Bhatt DL, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706–17.

    Article  PubMed  CAS  Google Scholar 

  76. Pfeffer MA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327(10):669–77.

    Article  PubMed  CAS  Google Scholar 

  77. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation. 1998;97(22):2202–12.

    Google Scholar 

  78. Chen JW, et al. Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am J Cardiol. 2002;90(9):974–82.

    Article  PubMed  CAS  Google Scholar 

  79. Pauly DF, et al. In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: a double-blind randomized study from the National Heart, Lung and Blood Institute Women’s Ischemia Syndrome Evaluation (WISE). Am Heart J. 2011;162(4):678–84.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  80. Truong QA, et al. Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22. Circ Cardiovasc Qual Outcomes. 2011;4(3):328–36.

    Article  PubMed Central  PubMed  Google Scholar 

  81. Mosca L, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women–2011 update: a guideline from the american heart association. Circulation. 2011;123(11):1243–62.

    Article  PubMed Central  PubMed  Google Scholar 

  82. Treasure CB, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332(8):481–7.

    Article  PubMed  CAS  Google Scholar 

  83. Lavigne PM, Karas RH. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am Coll Cardiol. 2013;61(4):440–6.

    Article  PubMed  CAS  Google Scholar 

  84. Group, C.D.P.R. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231(4):360–81.

    Article  Google Scholar 

  85. AIM-HIGH Investigators, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–67.

    Article  CAS  Google Scholar 

  86. Kernis SJ, et al. Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? J Am Coll Cardiol. 2004;43(10):1773–9.

    Article  PubMed  CAS  Google Scholar 

  87. Sarbaziha R, et al. Therapy for stable angina in women. P T. 2012;37(7):400–4.

    PubMed Central  PubMed  Google Scholar 

  88. Kayaalti F, et al. Effects of nebivolol therapy on endothelial functions in cardiac syndrome X. Heart Vessels. 2010;25(2):92–6.

    Article  PubMed  Google Scholar 

  89. Ezekowitz MD, et al. Amlodipine in chronic stable angina: results of a multicenter double-blind crossover trial. Am Heart J. 1995;129(3):527–35.

    Article  PubMed  CAS  Google Scholar 

  90. Brogden RN, Benfield P. Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease. Drugs. 1996;51(5):792–819.

    Article  PubMed  CAS  Google Scholar 

  91. Boman K, et al. Antianginal effect of conventional and controlled release diltiazem in stable angina pectoris. Eur J Clin Pharmacol. 1995;49(1–2):27–30.

    PubMed  CAS  Google Scholar 

  92. Thadani U. Current medical management of chronic stable angina. J Cardiovasc Pharmacol Ther. 2004;9 Suppl 1:S11–29; quiz S98–9.

    Article  PubMed  CAS  Google Scholar 

  93. Hunt SA, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53(15):e1–90.

    Article  PubMed  Google Scholar 

  94. Chaitman BR, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291(3):309–16.

    Article  PubMed  CAS  Google Scholar 

  95. Mehta PK, et al. Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease. JACC Cardiovasc Imaging. 2011;4(5):514–22.

    Article  PubMed  Google Scholar 

  96. Frampton J, Buckley MM, Fitton A. Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris. Drugs. 1992;44(4):625–55.

    Article  PubMed  CAS  Google Scholar 

  97. Chaitman BR, Sano J. Novel therapeutic approaches to treating chronic angina in the setting of chronic ischemic heart disease. Clin Cardiol. 2007;30(2 Suppl 1):I25–30.

    Article  PubMed  Google Scholar 

  98. Arora RR, et al. The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes. J Am Coll Cardiol. 1999;33(7):1833–40.

    Article  PubMed  CAS  Google Scholar 

  99. Di Pede F, et al. Immediate and long-term clinical outcome after spinal cord stimulation for refractory stable angina pectoris. Am J Cardiol. 2003;91(8):951–5.

    Article  PubMed  Google Scholar 

  100. Levine GN, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58(24):e44–122.

    Article  PubMed  Google Scholar 

  101. Patel MR, et al. ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 Appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol. 2012;59(9):857–81.

    Article  PubMed  Google Scholar 

  102. Hannan EL, et al. Risk stratification of in-hospital mortality for coronary artery bypass graft surgery. J Am Coll Cardiol. 2006;47(3):661–8.

    Article  PubMed  Google Scholar 

  103. Singh M, et al. Correlates of procedural complications and a simple integer risk score for percutaneous coronary intervention. J Am Coll Cardiol. 2002;40(3):387–93.

    Article  PubMed  Google Scholar 

  104. Kim C, et al. A systematic review of gender differences in mortality after coronary artery bypass graft surgery and percutaneous coronary interventions. Clin Cardiol. 2007;30(10):491–5.

    Article  PubMed  Google Scholar 

  105. Lundberg G, King S. Coronary revascularization in women. Clin Cardiol. 2012;35(3):156–9.

    Article  PubMed  Google Scholar 

  106. Duvernoy CS, et al. Gender differences in adverse outcomes after contemporary percutaneous coronary intervention: an analysis from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) percutaneous coronary intervention registry. Am Heart J. 2010;159(4):677–683 e1.

    Article  PubMed  Google Scholar 

  107. Anderson ML, et al. Short- and long-term outcomes of coronary stenting in women versus men: results from the National Cardiovascular Data Registry Centers for Medicare & Medicaid services cohort. Circulation. 2012;126(18):2190–9.

    Article  PubMed  Google Scholar 

  108. Mikhail GW, et al. Influence of sex on long-term outcomes after percutaneous coronary intervention with the paclitaxel-eluting coronary stent: results of the “TAXUS Woman” analysis. JACC Cardiovasc Interv. 2010;3(12):1250–9.

    Article  PubMed  Google Scholar 

  109. Berger PB, et al. Frequency of early occlusion and stenosis in a left internal mammary artery to left anterior descending artery bypass graft after surgery through a median sternotomy on conventional bypass: benchmark for minimally invasive direct coronary artery bypass. Circulation. 1999;100(23):2353–8.

    Article  PubMed  CAS  Google Scholar 

  110. BARI 2D Study Group, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503–15.

    Article  Google Scholar 

  111. Serruys PW, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360(10):961–72.

    Article  PubMed  CAS  Google Scholar 

  112. Kappetein AP, et al. Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J. 2011;32(17):2125–34.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, University of Rochester Medical Center, Rochester, NY, USA

    Rashaad A. Chothia MD & Jason Pacos MD

Authors
  1. Rashaad A. Chothia MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jason Pacos MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rashaad A. Chothia MD .

Editor information

Editors and Affiliations

  1. Division of Cardiology, University of Rochester Medical Center, Rochester, New York, USA

    Hanna Z. Mieszczanska

  2. Division of Cardiology, University of Florida College of Medicine Jacksonville, Jacksonville, Florida, USA

    Gladys P. Velarde

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag London

About this chapter

Cite this chapter

Chothia, R.A., Pacos, J. (2014). Management of Stable Ischemic Heart Disease in Women. In: Mieszczanska, H., Velarde, G. (eds) Management of Cardiovascular Disease in Women. Springer, London. https://doi.org/10.1007/978-1-4471-5517-1_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-5517-1_5

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-5516-4

  • Online ISBN: 978-1-4471-5517-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation